Investment
Features
FeesSafety
Academy
More
Pluang+

Compare International Business Machines Corp (IBM) vs Viatris Inc (VTRS) Price & Performance

International Business Machines CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

International Business Machines Corp vs Viatris Inc — how do they compare? International Business Machines Corp trades at $211.08 (market cap $200.20B), while Viatris Inc trades at $17.25 (market cap $19.79B). The key difference: International Business Machines Corp is far larger — about 10.1× Viatris Inc's market cap, and International Business Machines Corp pays the higher dividend (3.17%). Which is the better fit depends on your goals.

IBMVTRS
Market Cap
$200.20B$19.79B
Volume
4,481,527
Sector
TechnologyHealth
52-Week High
$329.23$17.39
52-Week Low
$211.20$8.74
Enterprise Value
$258.21B$32.00B
Dividend Yield
3.17%2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

International Business Machines Corp

IBM stock trades at $213.81, down 25% following disappointing Q2 2026 preliminary results that missed revenue and EPS estimates. The company maintains strong profitability with 58.4% gross margins and 15.6% net income margin, but faces execution challenges as customers shift spending toward AI infrastructure. Technical indicators show bearish momentum with support at $210 and resistance at $216, while analyst consensus remains positive with a $287.85 price target despite recent downgrades.

IBM's long-term fundamentals remain solid with consistent earnings beats and strong cash flow generation, but near-term headwinds from AI spending shifts create uncertainty. The stock offers value at current levels with attractive valuation multiples, though investors face execution risk and competitive pressure in the evolving AI landscape.

Viatris Inc

Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.

Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About International Business Machines Corp

International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.

Read more on IBM

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS